MX2017005148A - Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso. - Google Patents

Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.

Info

Publication number
MX2017005148A
MX2017005148A MX2017005148A MX2017005148A MX2017005148A MX 2017005148 A MX2017005148 A MX 2017005148A MX 2017005148 A MX2017005148 A MX 2017005148A MX 2017005148 A MX2017005148 A MX 2017005148A MX 2017005148 A MX2017005148 A MX 2017005148A
Authority
MX
Mexico
Prior art keywords
region polypeptide
igg class
region
variant
parent igg
Prior art date
Application number
MX2017005148A
Other languages
English (en)
Inventor
Moessner Ekkehard
Schlothauer Tilman
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2017005148A publication Critical patent/MX2017005148A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Compression Or Coding Systems Of Tv Signals (AREA)

Abstract

En la presente descripción se informa de una región Fc de clase IgG que comprende un primer polipéptido de región Fc variante y un segundo polipéptido de región Fc variante, en el que: a) el primer polipéptido de región Fc variante se deriva de un primer polipéptido de región Fc de clase IgG parental y el segundo polipéptido de región Fc se deriva de un segundo polipéptido de región Fc de clase IgG parental, de manera que el primer polipéptido de región Fc de clase IgG parenta]. es idéntico o diferente del segundo polipéptido de región Fc de clase IgG parental, y b) el primer polipéptido de región Fc variante difiere del segundo polipéptido de región Fc variante en uno o más residuos aminoácidos diferentes de los residuos aminoácidos en los que el primer polipéptido de región Fc de clase IgG parental difiere del segundo polipéptido de región Fc de clase IgG parental, y c) la región Fc de clase IgG que comprende el primer polipéptido de región Fc variante y el segundo polipéptido de región Fc variante presentan una afinidad para un receptor Fc humano que es diferente de la de una región Fc de clase IgG que comprende el primer polipéptido de clase IgG parental de a) y el segundo polipéptido de región Fc de clase IgG parental de a), en el que el primer polipéptido de región Fc o el segundo polipéptido de región Fc o ambos polipéptidos de región Fc comprenden independientemente uno de otro una de las mutaciones o combinaciones de mutaciones siguientes como se especifica en la solicitud región Fc comprenden independientemente uno de otro una de las mutaciones o combinaciones de mutaciones siguientes como se especifica en la solicitud.
MX2017005148A 2014-11-06 2015-11-04 Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso. MX2017005148A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14192052 2014-11-06
PCT/EP2015/075656 WO2016071376A2 (en) 2014-11-06 2015-11-04 Fc-region variants with modified fcrn-binding and methods of use

Publications (1)

Publication Number Publication Date
MX2017005148A true MX2017005148A (es) 2017-08-08

Family

ID=51947132

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017005148A MX2017005148A (es) 2014-11-06 2015-11-04 Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.
MX2020010061A MX2020010061A (es) 2014-11-06 2017-04-20 Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010061A MX2020010061A (es) 2014-11-06 2017-04-20 Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.

Country Status (20)

Country Link
US (2) US10683368B2 (es)
EP (2) EP3611188B1 (es)
JP (2) JP6707090B2 (es)
KR (1) KR20170078677A (es)
CN (1) CN107108720A (es)
AR (1) AR102521A1 (es)
BR (1) BR112017006178A2 (es)
CA (1) CA2960797A1 (es)
DK (1) DK3215528T3 (es)
ES (1) ES2749383T3 (es)
HR (1) HRP20191766T1 (es)
HU (1) HUE045466T2 (es)
LT (1) LT3215528T (es)
MX (2) MX2017005148A (es)
PL (1) PL3215528T3 (es)
PT (1) PT3215528T (es)
RS (1) RS59340B1 (es)
RU (1) RU2714116C2 (es)
SI (1) SI3215528T1 (es)
WO (1) WO2016071376A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860600C (en) 2012-02-15 2022-07-26 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
CA3016563A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CN110072887A (zh) 2016-08-02 2019-07-30 威特拉公司 工程化多肽及其应用
CN107698684B (zh) * 2016-08-03 2021-09-28 广东东阳光药业有限公司 包含突变的免疫球蛋白Fc部分的GLP-1融合蛋白
JP6993403B2 (ja) 2016-08-10 2022-03-03 アジュ ユニバーシティー インダストリー－アカデミック コーオペレイション ファウンデーション ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物
WO2018129714A1 (zh) * 2017-01-13 2018-07-19 杭州翰思生物医药有限公司 抗pd-1的单克隆抗体及其应用
EP3569615A4 (en) * 2017-01-13 2020-07-29 Hanx Biopharmaceutics, Inc PROCESS FOR IMPROVING THE BINDING AFFINITY OF AN IGG ANTIBODY TOWARDS FCRN AND PROLONGING THE SERIC HALF-LIFE OF THE latter
US20220213206A1 (en) * 2017-02-06 2022-07-07 Dana-Farber Cancer Institute, Inc. Compositions and methods for augmenting antibody mediated receptor signaling
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
FR3064007A1 (fr) * 2017-03-20 2018-09-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anticorps pour le traitement de cancers
EP3615678A1 (en) 2017-04-28 2020-03-04 H. Hoffnabb-La Roche Ag Antibody selection method
EP3630836A1 (en) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
AU2018314257A1 (en) * 2017-08-11 2020-02-13 Research Development Foundation Engineered antibody Fc variants for enhanced serum half life
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CA3076369A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
TW201940512A (zh) * 2018-01-26 2019-10-16 美商健臻公司 具有與ＦｃＲｎ增進的結合及延長的半衰期之Ｆｃ變異體
US20210009711A1 (en) 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
US20210238280A1 (en) 2018-03-14 2021-08-05 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN108640997A (zh) * 2018-05-22 2018-10-12 蔡毓旻 一种双特异性抗体
WO2019228406A1 (en) * 2018-05-29 2019-12-05 Wuxi Biologics (Shanghai) Co., Ltd. A novel anti-cd3/anti-cd20 bispecific antibody
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
PE20211279A1 (es) 2018-10-23 2021-07-19 Dragonfly Therapeutics Inc Proteinas heterodimericas fusionadas con fc
CN112955240B (zh) * 2018-10-25 2022-09-16 豪夫迈·罗氏有限公司 抗体FcRn结合的修饰
WO2020172601A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3130508A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
AU2020224680A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
EP3927744A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CA3131014A1 (en) 2019-02-21 2020-08-27 Andreas Loew Anti-tcr antibody molecules and uses thereof
KR20220038432A (ko) * 2019-07-25 2022-03-28 젠자임 코포레이션 FcRn 길항제를 이용한 항체-매개 장애의 치료 방법
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics Inc CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES
US11365233B2 (en) 2020-04-10 2022-06-21 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2021217085A1 (en) 2020-04-24 2021-10-28 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
KR20230074487A (ko) 2020-08-26 2023-05-30 마렝고 테라퓨틱스, 인크. Trbc1 또는 trbc2를 검출하는 방법
WO2022046920A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2022046922A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
MX2023004335A (es) 2020-10-14 2023-05-04 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas.
JP2023550785A (ja) * 2020-11-25 2023-12-05 ヴィア・バイオテクノロジー・インコーポレイテッド 複数のベータコロナウイルスに結合する抗体
KR20230157448A (ko) 2021-03-16 2023-11-16 싸이톰스 테라퓨틱스, 인크. 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법
BR112023020832A2 (pt) 2021-04-08 2023-12-19 Marengo Therapeutics Inc Moléculas multifuncionais ligadas a tcr e seus usos
WO2022265331A1 (ko) * 2021-06-14 2022-12-22 고려대학교 산학협력단 제어된 면역 작용 기작과 증가된 혈중 반감기를 갖는 fc변이체들
TW202334185A (zh) 2021-10-08 2023-09-01 美商Ｃｙｔｏｍｘ生物製藥公司 可經活化之細胞介素構築體和組合方法
CA3233663A1 (en) 2021-10-08 2023-04-13 Na CAI Activatable cytokine constructs and related compositions and methods

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4900660A (en) 1985-11-25 1990-02-13 University Of Florida Streptococcal fc rc
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5169936A (en) 1989-04-14 1992-12-08 Biogen, Inc. Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
MX9203138A (es) 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5623053A (en) 1992-01-10 1997-04-22 California Institute Of Technology Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5
JP3095175B2 (ja) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
IL118069A (en) 1995-05-02 2000-06-01 Japan Tobacco Inc Monoclonal antibody reactive to human CETP and assay method for human CETP
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6451308B1 (en) 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JP2001521909A (ja) 1997-10-31 2001-11-13 ジェネンテク・インコーポレイテッド 糖タンパク質グリコフォームを含む方法及び組成物
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
US6489447B1 (en) 1998-05-06 2002-12-03 Genentech, Inc. Protein purification
PT1082341E (pt) 1998-06-01 2011-02-15 Agensys Inc Antigénio de tumor útil em diagnóstico e terapêutica de cancro da próstata e do cólon
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
DK2270149T3 (en) 1999-04-09 2016-05-09 Kyowa Hakko Kirin Co Ltd PROCEDURE TO CONTROL THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE.
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2388245C (en) 1999-10-19 2012-01-10 Tatsuya Ogawa The use of serum-free adapted rat cells for producing heterologous polypeptides
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
CA2395660A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
EP1324776B2 (en) 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP1326897A2 (en) 2000-10-13 2003-07-16 Biogen, Inc. Humanized anti-lt-beta-r antibodies
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003073238A2 (en) 2002-02-27 2003-09-04 California Institute Of Technology Computational method for designing enzymes for incorporation of amino acid analogs into proteins
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
WO2003085118A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
WO2003085102A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
WO2003084570A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
KR20070055625A (ko) 2002-12-16 2007-05-30 제넨테크, 인크. 이뮤노글로불린 변이체 및 이들의 용도
JP2006523090A (ja) 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
US7230068B2 (en) 2003-10-09 2007-06-12 Ambrx, Inc. Polymer derivatives
EP1705251A4 (en) 2003-10-09 2009-10-28 Kyowa Hakko Kirin Co Ltd PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
LT2348051T (lt) 2003-11-05 2019-02-25 Roche Glycart Ag Cd20 antikūnai su padidintu fc receptoriaus prisijungimo giminingumu ir efektorine funkcija
CN1938046B (zh) 2003-11-06 2014-03-19 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
AU2005211385B2 (en) 2004-02-02 2008-12-11 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
SE0400501D0 (sv) 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
KR100891620B1 (ko) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-ｐ-셀렉틴 항체
EP1778728A2 (en) 2004-08-19 2007-05-02 Genentech, Inc. Polypeptide variants with altered effector function
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
PT2161336E (pt) 2005-05-09 2013-10-03 Ono Pharmaceutical Co Anticorpos monoclonais humanos para morte programada 1 (pd-1) e métodos de tratamento do cancro utilizando anticorpos anti- pd-1 sozinhos ou em combinação com outros agentes imunoterapêuticos¿
TWI391399B (zh) 2005-05-25 2013-04-01 Hoffmann La Roche 測定溶離多肽之鹽濃度之方法
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1790716A1 (en) 2005-11-23 2007-05-30 UMC Utrecht Holding B.V. Uses of the FcRn receptor
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
US7662930B2 (en) 2005-12-06 2010-02-16 Amgen Inc. Polishing steps used in multi-step protein purification processes
JP5474531B2 (ja) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作されたヘテロ二量体タンパク質ドメイン
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
EP1878739A1 (en) 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. One step IMAC (MCAC) purification of proteins
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008085988A1 (en) 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
WO2008103474A1 (en) 2007-02-20 2008-08-28 Anaptysbio, Inc. Methods of generating libraries and uses thereof
WO2008143199A1 (ja) 2007-05-21 2008-11-27 Nomadic Bioscience Co., Ltd. 新規ポリペプチド，アフィニティークロマトグラフィー用材，及びイムノグロブリンの分離及び／又は精製方法
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JP5064558B2 (ja) 2007-06-01 2012-10-31 エフ．ホフマン−ラ ロシュ アーゲー 免疫グロブリン精製
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
DK2235059T3 (en) * 2007-12-26 2015-03-30 Xencor Inc FC-VERSIONS OF MODIFIED BINDING TO FcRn
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
CN103251948A (zh) 2008-04-11 2013-08-21 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
US20100069617A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
PE20150682A1 (es) 2008-10-14 2015-05-20 Genentech Inc Variantes de inmunoglobulinas y sus usos
WO2010048313A2 (en) 2008-10-22 2010-04-29 Biogen Idec Ma Inc. Recombinant fcrn and variants thereof for purification of fc-containing fusion proteins
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
PL2417156T3 (pl) 2009-04-07 2015-07-31 Roche Glycart Ag Trójwartościowe, bispecyficzne przeciwciała
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
JP5719354B2 (ja) 2009-05-27 2015-05-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 三重又は四重特異性抗体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
TWI507525B (zh) * 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
WO2011028952A1 (en) * 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
DK2519543T3 (en) 2009-12-29 2016-09-26 Emergent Product Dev Seattle HETERODIMER BINDING PROTEINS AND USE THEREOF
WO2011106272A1 (en) 2010-02-23 2011-09-01 Merck Sharp & Dohme Corp. Novel binding assays useful in identifying antibodies with altered half-lives
WO2011110598A1 (en) 2010-03-10 2011-09-15 F. Hoffmann-La Roche Ag Method for purifying immunoglobulin solutions
CA2794860C (en) * 2010-03-30 2022-05-17 Chugai Seiyaku Kabushiki Kaisha Antibodies with modified affinity to fcrn that promote antigen clearance
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
WO2012125850A1 (en) * 2011-03-16 2012-09-20 Amgen Inc. Fc variants
EP2691417B1 (en) 2011-03-29 2018-08-01 Roche Glycart AG Antibody fc variants
JP6292718B2 (ja) 2011-07-01 2018-03-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 凝集ポリペプチドから単量体ポリペプチドを分離するための方法
JP2014527518A (ja) 2011-07-20 2014-10-16 ゼプテオン インコーポレイテッド ポリペプチド分離法
US9580501B2 (en) 2011-12-16 2017-02-28 Synthon Biopharmaceuticals B.V. Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
SI2794905T1 (sl) 2011-12-20 2020-08-31 Medimmune, Llc Modificirani polipeptidi za ogrodja bispecifičnega protitelesa
CA2860600C (en) 2012-02-15 2022-07-26 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
MX360110B (es) 2012-04-20 2018-10-23 Merus Nv Metodos y medios para la produccion de moleculas de tipo ig.
SG11201408646VA (en) * 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
EP3495387B1 (en) * 2012-07-13 2021-09-01 Roche Glycart AG Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
EA201891502A1 (ru) 2013-02-26 2018-12-28 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
CA2904806C (en) * 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
PL2992010T3 (pl) * 2013-04-29 2021-08-23 F.Hoffmann-La Roche Ag Modyfikowane asymetryczne przeciwciała wiążące receptor Fc i sposoby ich stosowania
MX2016011982A (es) 2014-03-21 2016-12-09 Hoffmann La Roche Prediccion in vitro de semivida in vivo de anticuerpos.
JP6288332B2 (ja) 2017-03-06 2018-03-07 東洋紡株式会社 新規なグルコース脱水素酵素

Also Published As

Publication number Publication date
EP3611188A1 (en) 2020-02-19
JP2018502143A (ja) 2018-01-25
WO2016071376A2 (en) 2016-05-12
JP6707090B2 (ja) 2020-06-10
RU2017117856A (ru) 2018-12-06
CN107108720A (zh) 2017-08-29
US11440971B2 (en) 2022-09-13
BR112017006178A2 (pt) 2018-05-02
DK3215528T3 (da) 2019-10-07
EP3611188B1 (en) 2022-05-04
US10683368B2 (en) 2020-06-16
PT3215528T (pt) 2019-10-11
CA2960797A1 (en) 2016-05-12
AR102521A1 (es) 2017-03-08
PL3215528T3 (pl) 2020-01-31
US20200270367A1 (en) 2020-08-27
RU2714116C2 (ru) 2020-02-11
EP3215528A2 (en) 2017-09-13
SI3215528T1 (sl) 2019-11-29
KR20170078677A (ko) 2017-07-07
US20170342167A1 (en) 2017-11-30
JP2020111588A (ja) 2020-07-27
RU2017117856A3 (es) 2019-08-08
EP3215528B1 (en) 2019-08-07
HRP20191766T1 (hr) 2019-12-27
LT3215528T (lt) 2019-10-25
MX2020010061A (es) 2020-10-15
RS59340B1 (sr) 2019-10-31
ES2749383T3 (es) 2020-03-20
HUE045466T2 (hu) 2019-12-30
WO2016071376A3 (en) 2016-06-30
JP7023306B2 (ja) 2022-02-21

Similar Documents

Publication Publication Date Title
MX2020010061A (es) Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.
MX2020003260A (es) Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso.
MX2016008540A (es) Variantes de region fc con propiedades de union al receptor fc neonatal (fcrn).
MX2016008539A (es) Variantes de region fc con propiedades de union a receptor fc neonatal (fcrn) modificadas y de union a proteina a mantenidas.
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
MX2016008782A (es) Variantes de region fc con union mejorada de la proteina a.
PH12018501882A1 (en) Binding proteins and methods of use thereof
PH12016502282A1 (en) Improved immunoglobulin variable domains
MX2022009875A (es) Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes.
IL279510A (en) Progranulin-FC polypeptide fusion proteins and their uses
SG10201909716RA (en) Modified j-chain
IL245484A0 (en) Interleukin-2 fusion proteins and their uses
MX2017006866A (es) Pares de unión para producción de péptidos.
MY191944A (en) Binding proteins and methods of use thereof
EP3274457A4 (en) Follistatin-related fusion proteins and uses thereof
MX2015012872A (es) Anticuerpos anti-tau y metodos de uso.
GB2570063B (en) Fusion protein and applications thereof
EP3543335A3 (en) Soluble intein fusion proteins and methods for purifying biomolecules
PH12020550930A1 (en) Human igg fc domain variants with improved effector function
EP3202774A4 (en) Antibody-binding polypeptide, antibody-binding fusion polypeptide, and adsorbent material
IL270917A (en) Recombinant ROBO2 proteins, preparations, methods and their use
EP3576767A4 (en) RECOMBINANT PROTEINS AND USES THEREOF
NZ746677A (en) Novel alpha-1-microglobulin derived proteins and their use
HK1251456A1 (zh) 免疫球蛋白融合蛋白及其用途
TH1501005499A (th) โพลีเปปไทด์ IL-22 และฟิวชันโปรตีน IL-22 Fc และวิธีการใช้